RLMD vs CVEO Comparison

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, and Australia. It derives maximum revenue from Australia.